- $9.69m
- $7.43m
- $19.19m
- 57
- 65
- 36
- 53
Annual cashflow statement for cbdMD, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -23.4 | -70.1 | -22.9 | -3.7 | -2.04 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 11.1 | 56.1 | 16.3 | 2.66 | 1.43 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.93 | -2.77 | 0.57 | -0.463 | -1.97 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -14.1 | -15 | -4.3 | -0.353 | -1.45 |
| Capital Expenditures | -0.342 | -0.689 | -0.298 | -0.29 | -0.184 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -2.21 | 0 | 1 | 0 | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2.55 | -0.689 | 0.702 | -0.29 | -0.184 |
| Financing Cash Flow Items | 0 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 28.2 | -4.04 | -1.32 | 1.3 | 1.45 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.6 | -19.7 | -4.92 | 0.655 | -0.191 |